{"DataElement":{"publicId":"7252807","version":"1","preferredName":"Concomitant Medication Name","preferredDefinition":"Verbatim medication name or treatments (include only treatments with data collection characteristics similar to medications), as defined by the sponsor.","longName":"CMTRT_SPD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6400400","version":"1","preferredName":"Concomitant Medication Domain Concomitant Agent","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to concomitant medication administration._A pharmaceutical agent other than agent(s) tested in a given protocol that is administered to or used by a subject either prior to or during the study. Supportive care and essential ancillary medications required by a treatment regimen should be clearly identified. A protocol complete instructions including appropriate indication, dosage, administration route, schedule, restrictions to use, and any other relevant data should be explicitly stated. Concept also refers to substance(s) used prior or during the study that are not specified by the protocol.","longName":"4550855v1.0:6400398v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"4550855","version":"1","preferredName":"Concomitant Medication Domain","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to concomitant medication administration.","longName":"C49568","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Concomitant Medication Domain","conceptCode":"C49568","definition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to concomitant medication administration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06047D53-A3ED-FF3E-E050-BB89AD430B5B","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-22","modifiedBy":"ONEDATA","dateModified":"2014-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6400398","version":"1","preferredName":"Concomitant Agent","preferredDefinition":"A pharmaceutical agent other than agent(s) tested in a given protocol that is administered to or used by a subject either prior to or during the study. Supportive care and essential ancillary medications required by a treatment regimen should be clearly identified. A protocol complete instructions including appropriate indication, dosage, administration route, schedule, restrictions to use, and any other relevant data should be explicitly stated. Concept also refers to substance(s) used prior or during the study that are not specified by the protocol.","longName":"C70902","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Concomitant Agent","conceptCode":"C70902","definition":"A pharmaceutical agent other than agent(s) tested in a given protocol that is administered to or used by a subject either prior to or during the study. Supportive care and essential ancillary medications required by a treatment regimen should be clearly identified. A protocol's complete instructions including appropriate indication, dosage, administration route, schedule, restrictions to use, and any other relevant data should be explicitly stated. Concept also refers to substance(s) used prior or during the study that are not specified by the protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7369ABB9-B659-44AD-E053-F662850A110C","latestVersionIndicator":"Yes","beginDate":"2018-08-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-14","modifiedBy":"ONEDATA","dateModified":"2018-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7369ABB9-B66A-44AD-E053-F662850A110C","latestVersionIndicator":"Yes","beginDate":"2018-08-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-14","modifiedBy":"KUMMEROA","dateModified":"2021-06-09","changeDescription":"Elevated to Standard per governance approval by RA. 2021-6-9 ak. 12/18/18 TT released/MC. created for CDASH 8/14/18LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7252803","version":"1","preferredName":"Concomitant Agent Clinical Study Sponsor Defined Name","preferredDefinition":"A pharmaceutical agent other than agent(s) tested in a given protocol that is administered to or used by a subject either prior to or during the study. Supportive care and essential ancillary medications required by a treatment regimen should be clearly identified. A protocol complete instructions including appropriate indication, dosage, administration route, schedule, restrictions to use, and any other relevant data should be explicitly stated. Concept also refers to substance(s) used prior or during the study that are not specified by the protocol._An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]_Clearly characterized or delimited._The words or language units by which a thing is known.","longName":"CMTRT_SPD","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"OTHER","valueDescription":"Other","ValueMeaning":{"publicId":"6424136","version":"1","preferredName":"Other","longName":"6424136","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"753441A1-068C-5A23-E053-F662850A6B7A","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-02","changeDescription":null,"administrativeNotes":"2023.2.2 Alt VM added per ticket request CADSR0002006. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3BD33F9-979F-017C-E053-F662850AEB52","beginDate":"2020-04-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-20","modifiedBy":"ONEDATA","dateModified":"2020-04-20","deletedIndicator":"No"},{"value":"IMMUNOTHERAPY","valueDescription":"Immunotherapy","ValueMeaning":{"publicId":"5102332","version":"1","preferredName":"Immunotherapy","longName":"5102332","preferredDefinition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29400305-01FA-73D5-E050-BB89AD437D83","latestVersionIndicator":"Yes","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3BD33F9-97B3-017C-E053-F662850AEB52","beginDate":"2020-04-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-20","modifiedBy":"ONEDATA","dateModified":"2020-04-20","deletedIndicator":"No"},{"value":"RADIATION THERAPY","valueDescription":"Radiation Therapy","ValueMeaning":{"publicId":"2567129","version":"1","preferredName":"Radiation Therapy","longName":"2567129","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D346-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-10-21","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-10-21","modifiedBy":"KUMMEROA","dateModified":"2023-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3BD33F9-97C7-017C-E053-F662850AEB52","beginDate":"2020-04-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-20","modifiedBy":"ONEDATA","dateModified":"2020-04-20","deletedIndicator":"No"},{"value":"SMALL MOLECULE","valueDescription":"Small Molecule","ValueMeaning":{"publicId":"7252804","version":"1","preferredName":"Small Molecule","longName":"7252804","preferredDefinition":"A molecule with a low molecular weight that is not determined by a genome sequence.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Small Molecule","conceptCode":"C48809","definition":"A molecule with a low molecular weight that is not determined by a genome sequence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3BD33F9-97D1-017C-E053-F662850AEB52","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-20","modifiedBy":"TAYLORT","dateModified":"2020-04-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3BD33F9-97EA-017C-E053-F662850AEB52","beginDate":"2020-04-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-20","modifiedBy":"ONEDATA","dateModified":"2020-04-20","deletedIndicator":"No"},{"value":"CHEMOTHERAPY","valueDescription":"Chemotherapy","ValueMeaning":{"publicId":"5102333","version":"1","preferredName":"Chemotherapy","longName":"5102333","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29400305-0232-73D5-E050-BB89AD437D83","latestVersionIndicator":"Yes","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3BD33F9-97FE-017C-E053-F662850AEB52","beginDate":"2020-04-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-20","modifiedBy":"ONEDATA","dateModified":"2020-04-20","deletedIndicator":"No"},{"value":"NONE","valueDescription":"None","ValueMeaning":{"publicId":"3030997","version":"1","preferredName":"None","longName":"3030997","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"82DD865C-2FEA-9DF4-E040-BB89AD434EAA","latestVersionIndicator":"Yes","beginDate":"2010-03-28","endDate":null,"createdBy":"CURTIST","dateCreated":"2010-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9DD1A14-A468-3171-E053-4EBD850A7111","beginDate":"2020-07-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-07","modifiedBy":"ONEDATA","dateModified":"2020-07-07","deletedIndicator":"No"},{"value":"UNKNOWN","valueDescription":"Unknown","ValueMeaning":{"publicId":"2960664","version":"1","preferredName":"Unknown","longName":"2960664","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78485FBD-4C65-D67B-E040-BB89AD432E0E","latestVersionIndicator":"Yes","beginDate":"2009-11-13","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-11-13","modifiedBy":"KUMMEROA","dateModified":"2023-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9DD1A14-A472-3171-E053-4EBD850A7111","beginDate":"2020-07-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-07","modifiedBy":"ONEDATA","dateModified":"2020-07-07","deletedIndicator":"No"},{"value":"PLASMA (FFP)","valueDescription":"Fresh Frozen Plasma","ValueMeaning":{"publicId":"7318725","version":"1","preferredName":"Fresh Frozen Plasma","longName":"7318725","preferredDefinition":"The plasma that is separated from the whole blood and frozen quickly after a blood donation in order to be used for blood transfusions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fresh Frozen Plasma","conceptCode":"C89783","definition":"The plasma that is separated from the whole blood and frozen quickly after a blood donation in order to be used for blood transfusions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A757D580-B81B-26D7-E053-4EBD850A4DBD","latestVersionIndicator":"Yes","beginDate":"2020-06-05","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-06-05","modifiedBy":"ONEDATA","dateModified":"2020-06-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9DDA641-5432-24A5-E053-4EBD850A86D6","beginDate":"2020-07-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-07","modifiedBy":"ONEDATA","dateModified":"2020-07-07","deletedIndicator":"No"},{"value":"CRYOPRECIPITATE","valueDescription":"Plasma Protein Cryoprecipitation","ValueMeaning":{"publicId":"7349867","version":"1","preferredName":"Plasma Protein Cryoprecipitation","longName":"7349867","preferredDefinition":"Initial separation of plasma proteins in the blood plasma fractionation process, followed by cooling to form precipitate. .","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasma Protein Cryoprecipitation","conceptCode":"C112940","definition":"A process to isolate plasma proteins by cooling the plasma to form a precipitate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9F06A76-86D2-0E46-E053-4EBD850A64DA","latestVersionIndicator":"Yes","beginDate":"2020-07-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-08","modifiedBy":"ONEDATA","dateModified":"2020-07-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9F06A76-86ED-0E46-E053-4EBD850A64DA","beginDate":"2020-07-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-08","modifiedBy":"ONEDATA","dateModified":"2020-07-08","deletedIndicator":"No"},{"value":"VITAMIN K ANTAGONISTS","valueDescription":"Vitamin K Antagonist","ValueMeaning":{"publicId":"7350385","version":"1","preferredName":"Vitamin K Antagonist","longName":"7350385","preferredDefinition":"Any agent that inhibits the function of vitamin K, with anticoagulant activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vitamin K Antagonist","conceptCode":"C173064","definition":"Any agent that inhibits the function of vitamin K, with anticoagulant activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA0449A4-34B8-507A-E053-4EBD850A64A2","latestVersionIndicator":"Yes","beginDate":"2020-07-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-09","modifiedBy":"TAYLORT","dateModified":"2020-07-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA7AE9FB-12F3-03B4-E053-4EBD850A2194","beginDate":"2020-07-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-15","modifiedBy":"ONEDATA","dateModified":"2020-07-15","deletedIndicator":"No"},{"value":"UNFRACTIONATED HEPARIN","valueDescription":"Heparin","ValueMeaning":{"publicId":"2567254","version":"1","preferredName":"Heparin","longName":"2567254","preferredDefinition":"A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Heparin","conceptCode":"C539","definition":"A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D3C3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA7AE9FB-12FE-03B4-E053-4EBD850A2194","beginDate":"2020-07-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-15","modifiedBy":"ONEDATA","dateModified":"2020-07-15","deletedIndicator":"No"},{"value":"LOW-MOLECULAR WEIGHT HEPARIN","valueDescription":"Low Molecular Weight Heparin","ValueMeaning":{"publicId":"7350384","version":"1","preferredName":"Low Molecular Weight Heparin","longName":"7350384","preferredDefinition":"Substances comprised of fragmented heparin molecules derived from unfractionated heparin that bind to antithrombin III with a molecular weight ranging from 1000 to 10,000 daltons, which causes changes in property from unfractionated heparin, including decreased protein binding, enhanced bioavailability, decreased platelet interaction, and decreased binding to thrombin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low Molecular Weight Heparin","conceptCode":"C2578","definition":"Substances comprised of fragmented heparin molecules derived from unfractionated heparin that bind to antithrombin III with a molecular weight ranging from 1000 to 10,000 daltons, which causes changes in property from unfractionated heparin, including decreased protein binding, enhanced bioavailability, decreased platelet interaction, and decreased binding to thrombin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA0449A4-3491-507A-E053-4EBD850A64A2","latestVersionIndicator":"Yes","beginDate":"2020-07-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-09","modifiedBy":"ONEDATA","dateModified":"2020-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA7AE9FB-1308-03B4-E053-4EBD850A2194","beginDate":"2020-07-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-15","modifiedBy":"ONEDATA","dateModified":"2020-07-15","deletedIndicator":"No"},{"value":"FONDAPARINUX","valueDescription":"Fondaparinux","ValueMeaning":{"publicId":"3191442","version":"1","preferredName":"Fondaparinux","longName":"3191442","preferredDefinition":"A synthetic glucopyranoside with antithrombotic activity. Fondaparinux selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin. Neutralization of Factor Xa inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fondaparinux","conceptCode":"C73142","definition":"A synthetic glucopyranoside with antithrombotic activity. Fondaparinux selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin. Neutralization of Factor Xa inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BF5A32C-4FAB-EC58-E040-BB89AD437BD3","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA7AE9FB-1313-03B4-E053-4EBD850A2194","beginDate":"2020-07-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-15","modifiedBy":"ONEDATA","dateModified":"2020-07-15","deletedIndicator":"No"},{"value":"DIRECT THROMBIN INHIBITOR","valueDescription":"Direct Thrombin Inhibitor","ValueMeaning":{"publicId":"7350383","version":"1","preferredName":"Direct Thrombin Inhibitor","longName":"7350383","preferredDefinition":"Any agent that directly binds to and inactivates thrombin (factor IIa), with anticoagulant activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Direct Thrombin Inhibitor","conceptCode":"C173066","definition":"Any agent that directly binds to and inactivates thrombin (factor IIa), with anticoagulant activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA0449A4-3453-507A-E053-4EBD850A64A2","latestVersionIndicator":"Yes","beginDate":"2020-07-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-09","modifiedBy":"ONEDATA","dateModified":"2020-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA7AE9FB-131E-03B4-E053-4EBD850A2194","beginDate":"2020-07-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-15","modifiedBy":"ONEDATA","dateModified":"2020-07-15","deletedIndicator":"No"},{"value":"DIRECT FACTOR XA INHIBITOR","valueDescription":"Direct Factor Xa Inhibitor","ValueMeaning":{"publicId":"7350382","version":"1","preferredName":"Direct Factor Xa Inhibitor","longName":"7350382","preferredDefinition":"Any agent that binds to and inactivates factor Xa, with anticoagulant activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Direct Factor Xa Inhibitor","conceptCode":"C173067","definition":"Any agent that binds to and inactivates factor Xa, with anticoagulant activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA0449A4-342C-507A-E053-4EBD850A64A2","latestVersionIndicator":"Yes","beginDate":"2020-07-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-09","modifiedBy":"ONEDATA","dateModified":"2020-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA7AE9FB-1329-03B4-E053-4EBD850A2194","beginDate":"2020-07-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-15","modifiedBy":"ONEDATA","dateModified":"2020-07-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7252802","version":"1","preferredName":"Concomitant Agent Clinical Study Sponsor Defined Name","preferredDefinition":"A pharmaceutical agent other than agent(s) tested in a given protocol that is administered to or used by a subject either prior to or during the study. Supportive care and essential ancillary medications required by a treatment regimen should be clearly identified. A protocol complete instructions including appropriate indication, dosage, administration route, schedule, restrictions to use, and any other relevant data should be explicitly stated. Concept also refers to substance(s) used prior or during the study that are not specified by the protocol.:An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]:Clearly characterized or delimited.:The words or language units by which a thing is known.","longName":"C70902:C70793:C165683:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Concomitant Agent","conceptCode":"C70902","definition":"A pharmaceutical agent other than agent(s) tested in a given protocol that is administered to or used by a subject either prior to or during the study. Supportive care and essential ancillary medications required by a treatment regimen should be clearly identified. A protocol's complete instructions including appropriate indication, dosage, administration route, schedule, restrictions to use, and any other relevant data should be explicitly stated. Concept also refers to substance(s) used prior or during the study that are not specified by the protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Clinical Study Sponsor","conceptCode":"C70793","definition":"An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Defined","conceptCode":"C165683","definition":"Clearly characterized or delimited.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3BD33F9-9779-017C-E053-F662850AEB52","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-20","modifiedBy":"ONEDATA","dateModified":"2020-04-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3BD33F9-978A-017C-E053-F662850AEB52","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-20","modifiedBy":"SOKKERL","dateModified":"2020-09-08","changeDescription":"4-20-20 Created for TRC-10446; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Concomitant Medication Name","type":"Preferred Question Text","description":"Concomitant Medication Name","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Which of the following was used to treat DIC?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Type of recent cancer therapy","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Which anti-coagulants were used?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Type of current anticoagulation?","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3BD29FA-CB47-7E8E-E053-F662850A01C5","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-20","modifiedBy":"SOKKERL","dateModified":"2020-09-08","changeDescription":"4-20-20 Created for TRC-10446; tmt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}